Wf-250 IV. VI Fine Pulverizer

Name: Wf-250 IV. VI Fine Pulverizer
Brand: Shanghai Pharmaceutical Machinery Co., Ltd.
SKU: 766451695

Shanghai, ChinaShanghai Pharmaceutical Machinery Co., Ltd.

Negotiable

1 Piece

Product profile

Crushing Degree

Fine Grinding Machine

Crushing Style

Grinding and Impact

Cutter Material

High-Speed Steel

Model NO.

Wf-250

Drive

Electric

Object

Metal

Type

Impact Crusher

Applied in

Food, Pharmaceutical and Chemical

Crushing Fineness

80-400 Mesh

Feeding Size

≤2mm

Weigh

280kg

Principle

Fixed Culling

Finished Surface

Outer Surface Process

Compressive Strength (For Crushing)

250-300MPA

Tongs' Features

Universal Tongs

Transport Package

Standard Export Wooden Cases

Specification

GMP, CE

Trademark

SPM

Origin

China

HS Code

8465990000

Production Capacity

50-100kg/H

Company profile

Experienced TeamExhibition ExperienceImporters and ExportersLow MOQ

Shanghai Pharmaceutical Machinery Co., Ltd.

Shanghai, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedCustomization Options: Customization from Samples, Customization from Designs, etc. CertifiedExport Year: 20 Years CertifiedNearest Port: Shanghai PortAverage Response Time: ≤5.98h CertifiedTerms of Payment: T/T, LC, PayPal, etc.

AI-Powered supplier vetting

SummaryThe supplier is identified as a Shanghai-based combined trading company with listed pharmaceutical equipment products and machining-related facilities. It reports extensive customization, R&D activity with new products in the past year, export experience of 20 years, and exports representing 90% of total sales. After-sales support includes repair services and overseas agents or branches, but no overseas warehouse or showroom. Finished-product inspection instructions are reportedly available and uniformly followed. The supplier does not provide ODM services, lacks an available SDK, and does not provide OEM services for well-known brands. Evidence is insufficient to verify certifications, detailed financial credibility, production scale, or named customer cases.

After-Sales capabilityThe supplier reports repair as an overseas service offering and states that it can provide services through overseas agents or branches. However, it has no overseas warehouse or showroom, so the evidence supports some service access but not comprehensive overseas infrastructure.

R&D capabilityThe supplier reports R&D capability and states that it launched new products during the past year. It does not have an available SDK and does not provide ODM services, but these limitations do not negate the explicit evidence of recent product development.

Production capacityThe supplier lists machining centers, CNC and milling equipment, provides a broad pharmaceutical-equipment product range, and reports a finished-product inspection method with instructions that are uniformly followed. However, the supplied data does not quantify production capacity, output, or manufacturing ownership, so production strength is only partially evidenced.

Customization capabilityBoth R&D and design-service records explicitly list customization from samples, designs, full customization, minor customization, and flexible customization. This is direct evidence of a broad customization offering.